LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...
HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for rare, common, chronic and age-associated diseases, announced that it has ...
A collaborative research team led by Professor Jinah Jang from the Department of Mechanical Engineering and the Department of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback